JointHealth™ express August 9, 2019
The latest news on provincial drug formulary listing decisions
Important news for people living with arthritis in Canada
This JointHealth™ express highlights the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), giant cell arteritis (a form of vasculitis), osteoporosis, and systemic juvenile idiopathic arthritis (sJIA).
Alberta
The following medication has been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The following medications have been listed for reimbursement on the provincial drug formulary:
The latest news on provincial drug formulary listing decisions
Important news for people living with arthritis in Canada
This JointHealth™ express highlights the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), giant cell arteritis (a form of vasculitis), osteoporosis, and systemic juvenile idiopathic arthritis (sJIA).
Alberta
The following medication has been listed for reimbursement on the provincial drug formulary:
- Etanercept (Erelzi®) for the treatment of PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
- Etanercept (Erelzi®) for the treatment of PsA
- Sarilumab (Kevzara®) for the treatment of RA
- Tocilizumab (Actemra®) for the treatment of giant cell arteritis, a form of vasculitis
The following medications have been listed for reimbursement on the provincial drug formulary:
- Tocilizumab (Actemra®) for the treatment of giant cell arteritis, a form of vasculitis
- Ixekizumab (Taltz®) for the treatment of PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
- Etanercept (Erelzi®) for the treatment of PsA
- Baricitinib (Olumiant®) for the treatment of RA
The following medications have been listed for reimbursement on the provincial drug formulary:
- Etanercept (Erelzi®) for the treatment of PsA
- Tocilizumab (Actemra®) for the treatment of giant cell arteritis, a form of vasculitis
- Ixekizumab (Taltz®) for the treatment of PsA
- A listing criteria change has occurred for denosumab (Prolia®) for the treatment of osteoporosis
The following medications have been listed for reimbursement on the provincial drug formulary:
- Canakinumab (Ilaris®) for the treatment of JIA
- Secukinumab (Cosentyx®) for the treatment of AS and PsA
- A listing criteria change has occurred for denosumab (Prolia®) for the treatment of osteoporosis
The following medications have been listed for reimbursement on the provincial drug formulary:
- Canakinumab (Ilaris®) for the treatment of sJIA
- Etanercept (Erelzi®) for the treatment of PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
- Ixekizumab (Taltz®) for the treatment of PsA
- Tocilizumab (Actemra®) for the treatment of giant cell arteritis, a form of vasculitis
- Baricitinib (Olumiant®) is an oral targeted small molecule treatment (TSMM) for rheumatoid arthritis. It works by interfering with the process in rheumatoid arthritis that leads to joint damage by targeting JAK1 and JAK3 of the Janus family of kinases (enzymes).
- Canakinumab (Ilaris®) is a biologic originator treatment for systemic juvenile idiopathic arthritis (sJIA) in patients two years and older. It is a human monoclonal antibody that inhibits interleukin-1 beta (a type of cytokine responsible for inflammation).
- Denosumab (Prolia®) is a biologic treatment for postmenopausal women with osteoporosis at high risk of fracture and used to increase bone mass in men with osteoporosis at high risk of fracture. It works by inhibiting the development and activation of osteoclasts (the cells that eat away bone).
- Etanercept (Erelzi®) is a biosimilar biologic treatment for rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. It works by blocking TNF (Tumor Necrosis Factor), a type of signalling protein (cytokine), that is involved in systemic inflammation.
- Ixekizumab (Taltz®) is a targeted small molecule treatment for psoriasis and psoriatic arthritis. It is currently being considered for the treatment of ankylosing spondylitis. It is an inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the inflammation associated with psoriasis and psoriatic arthritis.
- Secukinumab (Cosentyx®) is a biologic treatment for ankylosing spondylitis and psoriatic arthritis. It is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases.
- Tocilizumab (Actemra®) is a biologic treatment for rheumatoid arthritis, juvenile idiopathic arthritis, and giant cell arteritis (a form of vasculitis). It works by inhibiting or slowing down the body’s production of IL-6 (a protein that promotes inflammation when it is overly active).
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.